Background for Subcutaneous Amivantamab Plus Lazertinib in NSCLC

Luis E. Raez, MD, of Miami Cancer Institute, introduces COPERNICUS, a pragmatic phase 2b study of first-line subcutaneous amivantamab plus lazertinib in epidermal growth factor receptor–mutated advanced non–small cell lung cancer. The study enrolled at community and academic sites, eased entry criteria, and started every patient on a defined skin care regimen and 4 months of anticoagulation. Joined by Wade T. Iams, MD, of Tennessee Oncology, Dr Raez cautions that COPERNICUS is single arm, so comparisons with MARIPOSA are descriptive. He recalls that 34% of patients in MARIPOSA discontinued intravenous amivantamab because of adverse events, yet the combination still improved overall survival. Dr Raez then reviews the supportive care evidence: subcutaneous delivery in PALOMA-3 cut administration time to about 5 minutes from 2 to 5 hours, every-4-week dosing in PALOMA-2 produced an 82% response rate, and the COCOON regimen lowered grade 2 or higher dermatologic adverse events from 75% to 42%.